Home - Terapias innovadoras - RDGroups

Hematopoietic Innovative Therapies

“CIEMAT’s Hematopoietic Innovative Therapies group is focused on the development of translational research to improve the diagnosis and treatment of inherited and acquired pathologies through genetic, molecual and cellular biology techniques”

Investigadora del CIEMAT formará parte del Comité Científico Asesor de la Fanconi Anemia Research Foundation

Published 15/06/21
Células mesenquimales, soluciones para mejorar su eficacia.

Published 26/03/21
Un nuevo modelo celular de disqueratosis congénita ayudará a comprender la enfermedad y evaluar nuevas terapias

Published 08/02/21
Nuevos logros de la Unidad Mixta de Terapias Avanzadas CIEMAT-FIIS-FJD

Published 29/01/21
Un proyecto de terapia génica para la trombastenia de Glanzmann, dotado con 50.000 euros de la EAHAD

Published 12/02/20

News Highlights

Fanconi Anemia

Fanconi Anemia

A gene therapy clinical trial for patients with Fanconi Anemia offers its first successful results

Dyskeratosis Congenita

Dyskeratosis Congenita

A new cell model of dyskeratosis congenita will help understand the disease and evaluate new therapies

LAD-I immunodeficiency

LAD-I immunodeficiency

First successful results in gene therapy in a patient with LAD-I immunodeficiency